Paradigm Biocapital Advisors LP Merus N.V. Transaction History
Paradigm Biocapital Advisors LP
- $3.1 Billion
- Q3 2025
A detailed history of Paradigm Biocapital Advisors LP transactions in Merus N.V. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 300,000 shares of MRUS stock, worth $28.8 Million. This represents 0.91% of its overall portfolio holdings.
Number of Shares
300,000
Previous 4,281,954
92.99%
Holding current value
$28.8 Million
Previous $225 Million
87.46%
% of portfolio
0.91%
Previous 10.51%
Shares
9 transactions
Others Institutions Holding MRUS
# of Institutions
286Shares Held
65.4MCall Options Held
1.65MPut Options Held
758K-
Avoro Capital Advisors LLC New York, NY3.54MShares$340 Million4.56% of portfolio
-
Commodore Capital LP New York, NY3.53MShares$338 Million21.18% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.05MShares$292 Million5.34% of portfolio
-
Hbk Investments L P Dallas, TX2.85MShares$273 Million3.71% of portfolio
-
Westfield Capital Management CO LP Boston, MA2.13MShares$205 Million0.92% of portfolio
About Merus N.V.
- Ticker MRUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,878,200
- Market Cap $4.4B
- Description
- Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...